公开(公告)号：US12070506B2

公开(公告)日：2024-08-27

申请号：US16243020

申请日：2019-01-08

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Amy Han

IPC: A61K47/68 ,  A61K31/58 ,  A61K31/685 ,  A61K31/7048 ,  A61K47/54 ,  C07J71/00 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/6803 ,  A61K31/58 ,  A61K31/685 ,  A61K31/7048 ,  A61K47/542 ,  A61K47/545 ,  A61K47/549 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6889 ,  C07J71/0031 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/32 ,  C07K2317/41

Abstract: Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

公开(公告)号：US12065664B2

公开(公告)日：2024-08-20

申请号：US17128736

申请日：2020-12-21

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Dan Peer ,  Shiri Weinstein ,  Itai Antoine Toker ,  Srinivas Ramishetti

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/51 ,  A61K31/105 ,  A61K31/7105 ,  A61K31/713 ,  A61K47/68 ,  A61K47/69 ,  A61K48/00 ,  A61P35/02 ,  C07K16/28 ,  C12N15/88

CPC classification number: C12N15/88 ,  A61K9/0019 ,  A61K9/513 ,  A61K31/105 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/395 ,  A61K47/6849 ,  A61K47/6911 ,  A61K48/0066 ,  A61P35/02 ,  C07K16/2812 ,  C07K16/2896

Abstract: Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as siRNA) to leukocytes (such as T-Cells and B-cells). Further disclosed are uses of the targeted lipid based particles for treating Leukocytes-associated diseases, such as, cancer.

公开(公告)号：US12060433B2

公开(公告)日：2024-08-13

申请号：US17138306

申请日：2020-12-30

Applicant: Incyte Corporation

Inventor： Horacio G. Nastri ,  Shaun M. Stewart ,  Juan Carlos Almagro ,  Jing Zhou ,  Rebecca A. Buonpane ,  Hui Wang ,  Yingnan Chen ,  Xiaozhao Wang ,  Peter Niels Carlsen ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Wenyu Zhu ,  Taisheng Huang

IPC: C07K16/28 ,  A61K31/135 ,  A61K31/4985 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K31/135 ,  A61K31/4985 ,  A61P35/00 ,  A61K2039/505

Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

公开(公告)号：US12060432B2

公开(公告)日：2024-08-13

申请号：US17015017

申请日：2020-09-08

Applicant: Janssen Biotech, Inc.

Inventor： Parul Doshi

IPC: A61K39/00 ,  A61K31/00 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/573 ,  A61K31/65 ,  A61K31/675 ,  A61K31/704 ,  A61K39/395 ,  C07K16/28

CPC classification number: C07K16/2896 ,  A61K31/00 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/573 ,  A61K31/65 ,  A61K31/675 ,  A61K31/704 ,  A61K39/00 ,  A61K39/39558 ,  C07K16/2887 ,  A61K39/001126 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  A61K39/39558 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/475 ,  A61K2300/00 ,  A61K31/675 ,  A61K2300/00

Abstract: The present invention relates to combination therapies with anti-CD38 antibodies.

公开(公告)号：US12053490B2

公开(公告)日：2024-08-06

申请号：US16759263

申请日：2018-10-25

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Terrence L. Geiger ,  Wenting Zheng ,  Carol E. O'Hear

IPC: A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N15/00 ,  C12N15/62

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2896 ,  C12N15/00 ,  C12N15/62 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/03

Abstract: The application relates to a chimeric receptor that targets CD33 and allows activation of the co-stimulatory pathway without binding the natural ligand. The application also relates to polynucleotides that encode the chimeric receptor, vectors, and host cells comprising the chimeric receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo persistence of the chimeric antigen receptor host cells.

公开(公告)号：US20240247074A1

公开(公告)日：2024-07-25

申请号：US18417928

申请日：2024-01-19

Applicant: New York University

Inventor： Jiehui Deng ,  Kwok-Kin Wong ,  David Peng ,  Benjamin Neel ,  Hsin-Yi Huang

IPC: C07K16/28 ,  A61K31/353 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K35/00 ,  A61K45/06 ,  A61K47/68

CPC classification number: C07K16/2896 ,  A61K31/353 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/4709 ,  A61K35/00 ,  A61K45/06 ,  A61K47/6849

Abstract: Provided are methods for treatment of cancer by administering to an individual who has a cancer that includes cancer cells that have an LKBI mutation an anti-CD38 agent, an inhibitor of EP300, or a combination thereof. Methods are also provided for treating an individual who has a cancer that includes cancer cells that do not have an LKBI mutation a Salt-Inducible Kinase (SIK) inhibitor and an anti-CD38 agent. The SIK inhibitors sensitizes the cancer cells that do not have the LKBI mutation to the anti-CD38 agent.

公开(公告)号：US20240239879A1

公开(公告)日：2024-07-18

申请号：US18440895

申请日：2024-02-13

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/18 ,  A61K39/00 ,  C07K14/715 ,  C07K16/08 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K16/18 ,  C07K14/7151 ,  C07K16/082 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/90 ,  C07K2319/30 ,  Y02A50/30

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

公开(公告)号：US12037409B2

公开(公告)日：2024-07-16

申请号：US18022113

申请日：2021-01-08

Applicant: SHANGHAI GENBASE BIOTECHNOLOGY CO., LTD.

Inventor： Nan Mou ,  Yue Yu ,  Jijun Yuan

IPC: C07K16/00 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/565

Abstract: The present application provides an antibody specifically bound to glycosylated CEACAM5, the preparation of a humanized antibody thereof and an application thereof.

公开(公告)号：US12037407B2

公开(公告)日：2024-07-16

申请号：US18311856

申请日：2023-05-03

Applicant: Arsenal Biosciences, Inc.

Inventor： Jasper Williams ,  Michelle Nguyen ,  Anzhi Yao ,  Stephen Santoro ,  Aaron Cooper ,  John Gagnon ,  Adam Litterman ,  Omar Khan ,  Natalie Bezman ,  Katherine Harris ,  Harbani Kaur Malik Chaudhry ,  Nicole Allen

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2896 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: Provided herein are recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX. Also provided are systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX, cells expressing such proteins and shRNA, and methods of use thereof.

公开(公告)号：US20240228662A9

公开(公告)日：2024-07-11

申请号：US18235550

申请日：2023-08-18

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Yvo GRAUS ,  Judith OPRINS ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Martine VAN VUGT

IPC: C07K16/40 ,  A61K39/395 ,  A61K49/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/10 ,  C12N15/63 ,  G01N33/566

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K49/0004 ,  C07K14/70596 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  G01N33/566 ,  A61K2039/505 ,  C07K2317/34

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.